

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

Hs 746.T

RRID:CVCL_0333

Type: Cell Line

Proper Citation

CCTCC Cat# GDC0069, RRID:CVCL_0333

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0333

Proper Citation: CCTCC Cat# GDC0069, RRID:CVCL_0333

Description: Cell line Hs 746.T is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Gastric adenocarcinoma

Defining Citation: [PMID:283258](#), [PMID:761205](#), [PMID:6500159](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:24807215](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:29435981](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Characteristics: MET-amplified, contains 13-14 copies of the gene (PubMed=29435981)., Population: Caucasian., Part of: MET genetic alteration cell panel (ATCC TCP-1036)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Hs 746.T

Synonyms: Hs 746T, HS 746T, Hs-746T, HS-746T, Hs746T, HS746T, Hs746-T, 746T

Cross References: CLO:CLO_0004094, EFO:EFO_0006589, MCCL:MCC:0000229, AddexBio:C0023003/4957, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-135, BioSample:SAMN03470907, BioSample:SAMN03472714, BioSample:SAMN10987647, cancercellines:CVCL_0333, CCRID:4201HUM-CCTCC00069, CCTCC:GDC0069, Cell_Model_Passport:SIDM00665,

ChEMBL-Cells:CHEMBL3307498, ChEMBL-Targets:CHEMBL614579, CLS:305121, Cosmic:1187275, Cosmic:1329184, Cosmic:1460704, Cosmic:1479630, Cosmic:1482075, Cosmic:1995447, Cosmic:2069776, Cosmic:2484963, Cosmic-CLP:1240151, DepMap:ACH-000616, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240151, GEO:GSM267418, GEO:GSM267425, GEO:GSM267432, GEO:GSM267439, GEO:GSM552359, GEO:GSM562402, GEO:GSM827402, GEO:GSM844566, GEO:GSM887115, GEO:GSM888186, GEO:GSM1237674, GEO:GSM1237699, GEO:GSM1374552, GEO:GSM1669898, KCB:KCB 2013048YJ, LiGeA:CCE_544, LINCS_LDP:LCL-1883, PharmacoDB:Hs746T_594_2019, PRIDE:PXD030304, Progenetix:CVCL_0333, PubChem_Cell_line:CVCL_0333, Wikidata:Q54895986

ID: CVCL_0333

Vendor: CCTCC

Catalog Number: GDC0069

Record Creation Time: 20220427T220609+0000

Record Last Update: 20260905T180755+0000

Ratings and Alerts

No rating or validation information has been found for Hs 746.T.

No alerts have been found for Hs 746.T.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 20 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Santander GN, et al. (2026) Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. Cell reports methods, 101515.

Xie YL, et al. (2026) Ubiquitin Specific Peptidase 48 Deubiquitinates METTL3 to Modulate Ferroptosis in Gastric Cancer Cells. Molecular carcinogenesis.

Molotkova A, et al. (2026) ROME, an Ancient Gene with a Novel Function in Vertebrates, Is a Key Modulator of Embryonal Development and Cancer Metastasis. Cancer research communications, 6(3), 477.

Lu Y, et al. (2026) GAL3ST1-Mediated Histone Tyrosine Sulfation Induced by Cancer-Associated Fibroblasts Promotes Gastric Cancer Metastasis. Cancer research, 86(10),

Stamati I, et al. (2025) Anti-HER2, High-DAR Antibody Fragment-Drug Conjugates with a Glucuronide-Based MMAE Linker-Payload Demonstrate Superior Efficacy over IgG-Based ADCs. *Molecular cancer therapeutics*, 24(9), 1295.

Febres-Aldana CA, et al. (2025) Pan-Cancer Analysis of Oncogenic MET Fusions Reveals Distinct Pathogenomic Subsets with Differential Sensitivity to MET-Targeted Therapy. *Cancer discovery*, 15(6), 1141.

Li B, et al. (2025) Manipulating the cGAS-STING Axis: advancing innovative strategies for osteosarcoma therapeutics. *Frontiers in immunology*, 16, 1539396.

Wang Y, et al. (2025) Homeodomain protein PRRX1 anchors the Ku heterodimers at DNA double-strand breaks to promote nonhomologous end-joining. *Nucleic acids research*, 53(6).

Lorenz L, et al. (2024) Vorinostat Treatment of Gastric Cancer Cells Leads to ROS-Induced Cell Inhibition and a Complex Pattern of Molecular Alterations in Nrf2-Dependent Genes. *Pharmaceuticals (Basel, Switzerland)*, 17(8).

Tan KT, et al. (2024) Neotelomeres and telomere-spanning chromosomal arm fusions in cancer genomes revealed by long-read sequencing. *Cell genomics*, 4(7), 100588.

Fang M, et al. (2023) E3 ligase MG53 suppresses tumor growth by degrading cyclin D1. *Signal transduction and targeted therapy*, 8(1), 263.

Yu J, et al. (2023) VPS35 promotes cell proliferation via EGFR recycling and enhances EGFR inhibitors response in gastric cancer. *EBioMedicine*, 89, 104451.

Liu C, et al. (2023) Cell-to-cell variability in Myc dynamics drives transcriptional heterogeneity in cancer cells. *Cell reports*, 42(4), 112401.

Guo Z, et al. (2023) Tumor-promoting action of ubiquitin protease 43 in gastric cancer progression through deubiquitination and stabilization of stress-inducible phosphoprotein 1. *Experimental cell research*, 430(2), 113714.

Umeda S, et al. (2022) Lysosomal-associated membrane protein family member 5 promotes the metastatic potential of gastric cancer cells. *Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association*, 25(3), 558.

Orlando E, et al. (2022) An oncogene addiction phosphorylation signature and its derived scores inform tumor responsiveness to targeted therapies. *Cellular and molecular life sciences : CMLS*, 80(1), 6.

Sakai H, et al. (2021) Folate receptor ?? increases chemotherapy resistance through stabilizing MDM2 in cooperation with PHB2 that is overcome by MORAb-202 in gastric cancer. *Clinical and translational medicine*, 11(6), e454.

Li F, et al. (2021) Identification of ARGLU1 as a potential therapeutic target for gastric cancer based on genome-wide functional screening data. *EBioMedicine*, 69, 103436.

Yoon SJ, et al. (2020) Deconvolution of diffuse gastric cancer and the suppression of CD34 on the BALB/c nude mice model. BMC cancer, 20(1), 314.

Alarcón MA, et al. (2020) The Reprimo-Like Gene Is an Epigenetic-Mediated Tumor Suppressor and a Candidate Biomarker for the Non-Invasive Detection of Gastric Cancer. International journal of molecular sciences, 21(24).